PLA2G7 and coronary artery disorder: Secondly, the studies did not target a specific degree of Lp-PLA2 inhibition that has efficacy, although darapladib achieved an approximate reduction in Lp-PLA2 of 66% in the SOLID trial [30] and 65% in the STABILITY trial [11]; in addition, many cardiovascular events that occur early after ACS or in stable CHD may be more associated with thrombotic mechanisms and may not be modifiable through Lp-PLA2 inhibition.